Evidence map›Paper›PMID 27151513›Full record

ArticleJournal of the American Heart Association2016

Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System.

Rebecca Vigen, Thomas M Maddox, Colin I O'Donnell, Gary K Grunwald, Deepak L Bhatt, Thomas T Tsai, John S Rumsfeld, P Michael Ho

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca VigenThe University of Texas at Southwestern Medical Center, Dallas, TX.
Thomas M MaddoxVA Eastern Colorado Health Care System, Denver, CO University of Colorado Denver, Aurora, CO Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO.
Colin I O'DonnellVA Eastern Colorado Health Care System, Denver, CO.
Gary K GrunwaldVA Eastern Colorado Health Care System, Denver, CO University of Colorado Denver, Aurora, CO.
Deepak L BhattVA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA.
Thomas T TsaiVA Eastern Colorado Health Care System, Denver, CO University of Colorado Denver, Aurora, CO Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO.
John S RumsfeldVA Eastern Colorado Health Care System, Denver, CO University of Colorado Denver, Aurora, CO Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO.
P Michael HoVA Eastern Colorado Health Care System, Denver, CO University of Colorado Denver, Aurora, CO Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO michael.ho@va.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPremature clopidogrel discontinuation after drug-eluting stent placement is associated with adverse outcomes. Little is known about patient and hospital factors associated with premature discontinuation or whether less variation in premature discontinuation exists in integrated health care systems such as the Veterans Affairs (VA). METHODS AND

resultsWe evaluated the frequency of premature clopidogrel discontinuation, defined as a gap between clopidogrel refills of ≥90 days during the first 6 months of treatment, among 12 707 patients who received drug-eluting stents in VA hospitals between 2008 and 2010. We evaluated the association between premature discontinuation and all-cause mortality and/or acute myocardial infarction, variation in the proportion of premature discontinuation among hospitals, the patient and hospital characteristics associated with premature discontinuation, and the extent to which unexplained hospital characteristics contribute to premature discontinuation. Of the patients, 963 (7.6%) discontinued clopidogrel prematurely. Premature discontinuation was associated with acute myocardial infarction and all-cause mortality (hazard ratio 1.65, 95% CI 1.37-1.99, P<0.001). The proportion of patients with premature discontinuation varied across hospitals from 0% to 16.5% (P<0.001). We found a median of 24% greater odds of patients with identical covariates with premature discontinuation at one randomly selected hospital compared with another (median odds ratio 1.24, 95% CI 1.17-1.44). Patient factors associated with premature discontinuation included lack of cardiology follow-up within 30 days of discharge and smaller initial clopidogrel fill.

conclusionOne in 13 patients prematurely discontinued clopidogrel, and variation in discontinuation across hospitals was observed. Patient factors were associated with premature discontinuation that may represent targets for quality improvement.

Indexed as

DeprescriptionsDrug-Eluting StentsHospitalsMortalityAftercareAgedCardiologyCause of DeathClopidogrelCoronary Artery DiseaseFemaleHumansMaleMiddle AgedMyocardial InfarctionOdds RatioClopidogrelPlatelet Aggregation InhibitorsTiclopidineadherenceclopidogreldrug‐eluting stents

Identifiers

PMID27151513
PMCPMC4889159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.